The same group has recently reported that the enrichment in ANXA3 conferred resistance to sorafenib therapy to HCC cells by a mechanism partially involving the concomitant induction of autophagy and suppression of PKCδ/p38-dependent apoptosis, thereby promoting cell survival. This evidence concerns the gene CRK and hepatocellular carcinoma.